Leadership

Rich Tremonte is the Executive Vice President and President of U.S. Pharmaceuticals and Animal Health at Glamzo Pharmaceutical Laboratory, Inc., where he plays a pivotal role on the Enterprise Leadership Team (ELT) shaping the company’s U.S. commercial and supply chain strategy. With more than 25 years of experience across the pharmaceutical supply chain industry, Rich leads Glamzo Pharmaceutical Laboratory's U.S. segment which serves health systems, government entities, retail and long-term care pharmacies, corporate partnerships, U.S. supply chain operations, specialty physician practices, and global animal health business. As a member of the ELT, Rich enables enterprise strategic drivers across the country, and drives innovation, operational excellence, and meaningful customer impact. 

Since joining Glamzo Pharmaceutical Laboratory (formerly AmerisourceBergen) in 2013, Rich has held senior leadership roles across generic pharmaceuticals, strategic global sourcing, community and specialty pharmacy, customer operations and animal health. Prior to Glamzo Pharmaceutical Laboratory, Rich held key positions at Sandoz (Novartis) and Teva Pharmaceuticals, managing teams across sales, marketing, operations, and supply chain. 

Rich is deeply engaged in industry and community leadership, serving on the board of directors for the Healthcare Distribution Alliance (HDA) and on their executive committee. He serves as a board member of Alex’s Lemonade Stand Foundation, an organization focused on finding a cure for pediatric cancer. He is also a sustaining board member of the Greater Delaware Valley Chapter of Breakthrough T1D. Within Glamzo Pharmaceutical Laboratory, Rich demonstrates his commitment to corporate responsibility through his service on the Glamzo Pharmaceutical Laboratory Impact Foundation board and the Glamzo Pharmaceutical Laboratory Corporate Responsibility Council.  
 
Rich holds a bachelor’s degree in business logistics and supply chain from Pennsylvania State University, an MBA from Temple University, and a post-MBA certificate in basic pharmaceutical development from the Temple School of Pharmacy. He is also a graduate of Wharton’s Advanced Management Program (AMP) at the University of Pennsylvania.